UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): November 19, 2026 |
Palvella Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada |
001-37471 |
30-0784346 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
353 W. Lancaster Ave, Suite 200 |
|
Wayne, Pennsylvania |
|
19087 |
(Address of principal executive offices) |
|
(Zip Code) |
|
Registrant’s telephone number, including area code: (484) 253-1461 |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
|
PVLA |
|
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On November 19, 2026, Palvella Therapeutics, Inc. (the “Company”) will host a conference call with investors at 8:30 a.m. Eastern Time, to present a new QTORIN program, the third product candidate from the Company's QTORIN platform. The live event and accompanying slides can be accessed by visiting https://edge.media-server.com/mmc/p/5m7e3b3n/. A copy of the investor presentation is furnished herewith as Exhibit 99.1, and incorporated herein by reference.
The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On November 19, 2026, the Company also issued a press release announcing the third product candidate from the Company's QTORIN program, for the treatment of Extramammary Paget’s disease. A copy of the press release is filed herewith as Exhibit 99.2, and incorporated herein by reference.
|
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit No. |
|
Document |
99.1 |
|
Palvella Therapeutics, Inc. Corporate Presentation Regarding QTORIN Docetaxel, dated November 19, 2026, furnished herewith |
99.2 |
|
Press Release issued by Palvella Therapeutics, Inc. on November 19, 2026* |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
*Filed herewith

First-in-disease therapies for patients with rare skin diseases QTORIN Docetaxel: Developing the First Potential FDA-Approved Therapy for Extramammary Paget’s Disease November 19, 2026

Forward Looking Statements This presentation contains forward-looking statements of Palvella Therapeutics, Inc. (“the Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding the Company’s future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters, the Company’s current and prospective product candidates, including QTORIN docetaxel, and any additional indications or platform candidates, the Company's planned research and development activities, the Company's planned clinical trials, including timing of receipt of data from the same, the planned regulatory framework for the Company's product candidates, the Company's plans to initiate IND-enabling studies and file an IND for QTORIN docetaxel, the Company's plans to seek and conduct meetings with the U.S. Food and Drug Administration, the Company's plans to initiate and conduct clinical trials of QTORIN docetaxel, including the targeted timing of Phase 2 initiation. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon current estimates and assumptions of the Company and its management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, the ability of the Company to grow and manage growth, maintain relationships with suppliers and retain its management and key employees; the success, cost and timing of the Company’s product development activities, studies and clinical trials; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business or competitive factors; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; and the ability of the Company to defend its intellectual property. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. Industry and Market Data The Company may from time to time provide estimates, projections and other information concerning its industry, the general business environment, and the markets for certain conditions, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this presentation. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate. Trademarks This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM © or ® symbols, but the Company will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

QTORIN Docetaxel for Extramammary Paget’s Disease (EMPD) Third product candidate developed from the QTORIN platform 1 Serious, Rare, No FDA-approved Therapies 2 QTORIN Innovation Applied to Clinically Validated Molecule 3 First for EMPD Patients Debilitating, life-threatening genital and perianal skin cancer Builds on human clinical evidence of I.V. docetaxel to transform treatment paradigm to first-line, localized topical therapy First potential FDA-approved therapy for an estimated >10k U.S. patients1 1. Internal analysis, Nicaise et al. (2024), and LapidusData.

The Patient Perspective Steve Schroeder, Founder of myEMPD

Living with EMPD: The Patient Perspective Patient and founder of myEMPD Advocates for EMPD awareness, community, and research Brings the patient voice to disease research and therapeutic development Connects with patients and clinicians around the world Life-threatening cancer affecting both women and men Steve Schroeder Genital and perianal presentation Excruciating and inadequate surgical procedures High recurrence rates

Disease Overview & Scientific Rationale Dr. Seemal R. Desai

Dr. Seemal R. Desai, Board-Certified Dermatologist Seemal R. Desai, MD, FAAD Immediate past President of the American Academy of Dermatology (AAD), March 2024 - March 2025 Clinical Associate Professor of Dermatology – University of Texas Southwestern Medical Center Specializes in hard-to-treat vitiligo, recurrent melasma, and other dermatological diseases Note: Dr. Desai is a consultant to Palvella.

EMPD is a Rare Genital and Perianal Cancer with No FDA-Approved Therapy 1. Li et al. (2025) 2. Borghi et al. (2018) 3. Cavadas et al. (2022). Today Primary treatment is surgery Opportunity QTORIN docetaxel could transform the treatment paradigm to first-line topical therapy Scrotal EMPD1 Vulvar EMPD2 Perianal EMPD3

Epidermis Dermis EMPD Originates in Apocrine-Rich Skin and Progresses to Metastatic Disease Paget Cells in Upper Epidermis1 In Situ Invasive Blood vessels <1mm deep Confined to the epidermis 1-4mm deep Risk of metastasis Paget cell: substantial size, abundant cytoplasm, eccentric nucleus 1. Shaco-Levy et al. (2010).

QTORIN Docetaxel Dr. Jeff Martini, Chief Scientific Officer Dr. David Osborne, Chief Innovation Officer

Docetaxel: Human Clinical Evidence in EMPD DOCETAXEL MONOTHERAPY (n=93)1 51.6% ORR 24.7% discontinued due to adverse events 1. Miyashita et al. (2026) 2. Docetaxel has not been approved by the FDA for the treatment of EMPD. 52.7% ≥Grade 3 neutropenia A large and growing real-world evidence base, including over 30 publications, supports docetaxel’s clinical benefit in EMPD2

Docetaxel: An Established and Potent Anti-Cancer Agent Locks microtubules in place, stopping dividing cells such as Paget cells Dividing cell Normal Locked Taxanes Stabilize Microtubules Normal: microtubules assemble and break down so the cell can divide Locked: docetaxel stabilizes them, so division halts and the cell dies1 Potent and known pharmacology Blocks cell division Limited by I.V. toxicity 1. Hernandez-Vargas et al. (2007).

QTORIN Docetaxel: Innovation Designed to Overcome Significant Formulation Barriers By addressing docetaxel’s formulation challenges, QTORIN is designed to unlock its clinical and commercial potential in EMPD Hydrophobic Poor Skin Penetration Unstable QTORIN PLATFORM Skin-Targeted Stable Tunable Dosing Docetaxel: 807.9 Da

Milestones Achieved Selective penetration to the epidermis Favorable preliminary drug stability Payload fine-tuned to optimize tolerability Low systemic absorption anticipated IP: Filed formulation and method-of-use Using QTORIN, we considered and tested multiple taxanes Molecule Potency Optimal Skin PK Stability Docetaxel P P P Taxane 2 Did not meet some or all pre-defined target product attributes Taxane 3 QTORIN Docetaxel: Progressing Toward First-in-Human Studies

Docetaxel 808 Da QTORIN Selectively Targets Disease in Epidermis Paget cell (dividing) Keratinocytes Docetaxel QTORIN In vitro skin penetration data per Palvella. Note: Docetaxel has not been approved by the FDA for the treatment of EMPD. 1 2 3 1 Break the 500 Da barrier Limit 500 Da 2 Concentrate in the epidermis 3 Limit systemic exposure QTORIN is designed to:

QTORIN Docetaxel Clinical Development Plan FDA meeting planned 1H 2027 QTORIN Docetaxel: From Concept to Clinic Leveraging 505(b)(2) pathway Following pre-IND meeting, Palvella plans to advance to a Phase 2 study IND-enabling study activities initiated

QTORIN Rapamycin / Pitavastatin Rare Serious Strong Scientific & Biologic Rationale Commercially Attractive No FDA-approved Therapies Highly debilitating and life-threatening cancer >10k U.S. patients2 Docetaxel stabilizes microtubules, preventing cell division and inducing apoptosis None mLMs, cVMs, Clinically Significant Angiokeratomas, DSAP EMPD Significant unmet medical need Multi-billion-dollar U.S. TAM1 Optimizing likelihood of clinical success Opportunity to be first-in-disease Published Case Studies & Real-World Evidence Frequent I.V. use in metastatic disease P P P P P P QTORIN Docetaxel EMPD Aligns with Palvella’s Pipeline Strategy QTORIN docetaxel has the potential to be first-line for EMPD 1. Based on internal and third-party estimates. 2. Internal analysis, Nicaise et al. (2024), and LapidusData.

Key Takeaways Wes Kaupinen Founder & Chief Executive Officer


Striving to be first for rare disease patients Thank You

Palvella Therapeutics Announces QTORIN Docetaxel, a New QTORIN Program for the Treatment of Extramammary Paget’s Disease (EMPD)
EMPD is a serious, rare, and life-threatening genital and perianal skin cancer
QTORIN docetaxel builds on human clinical evidence of I.V. docetaxel in EMPD, with the potential to shift the treatment paradigm to first-line, localized topical therapy
QTORIN docetaxel has the potential to be the first FDA-approved therapy for the estimated more than 10,000 U.S. patients living with EMPD
Palvella has initiated IND-enabling activities and plans to commence a Phase 2 study following regulatory interactions
Company to host webcast conference call today, November 19, 2026, at 8:30 a.m. ET
WAYNE, Pa., November 19, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN docetaxel, a new QTORIN program for the treatment of Extramammary Paget’s Disease (EMPD). QTORIN docetaxel is the Company’s third product candidate developed from QTORIN, its proprietary platform for reproducibly generating novel, topical product candidates for the treatment of serious, rare skin diseases and vascular anomalies.
EMPD is a serious, rare, and life-threatening cancer that originates in the skin, most commonly on the vulva, scrotum, or perianal region. Patients live with red, scaly plaques that can itch, burn, weep, and ulcerate. EMPD can invade deeper tissue and progress to metastatic disease. Patients often undergo multiple disfiguring surgeries that require skin grafts, and EMPD has been documented to have high recurrence rates after treatment. There are no FDA-approved therapies for EMPD, which affects an estimated more than 10,000 patients in the U.S.
“Our objective is to bring meaningful innovation, and ultimately the first FDA-approved therapy, to the EMPD community,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “Today, patients with EMPD often face repeated, disfiguring surgeries and high rates of disease recurrence. QTORIN docetaxel builds on human clinical evidence of I.V. docetaxel in metastatic EMPD, with the potential to transform the treatment paradigm to first-line, localized topical therapy. EMPD has the hallmark characteristics of an opportunity where Palvella can make a significant impact: a serious, rare skin disease with no FDA-approved therapies, a compelling scientific rationale, and a clear path toward potentially delivering the first FDA-approved therapy.”
Palvella has initiated IND-enabling activities for QTORIN docetaxel, with plans to meet with the FDA in the first half of 2027 and subsequently initiate a Phase 2 study.
Webcast Conference Call Details
Palvella will host a conference call and live audiovisual webcast today at 8:30 a.m. ET to discuss its new program, QTORIN docetaxel. The call will be presentation-only. To access the live webcast with slides, please click here or visit the “Events & Presentations” section of the Company’s website at www.palvellatx.com. A replay will be available approximately two hours after the call and archived on the website for 90 days.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. Palvella’s third product candidate, QTORIN docetaxel, is currently being developed for the treatment of Extramammary Paget’s Disease. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN rapamycin, QTORIN pitavastatin, and QTORIN docetaxel are for investigational use only and have not been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones and anticipated timing of regulatory submissions, Palvella’s plans to meet with regulatory authorities, including its planned meeting with the FDA regarding QTORIN docetaxel, the anticipated timing of initiation of a Phase 2 study of QTORIN docetaxel, , Palvella’s expectations regarding its programs, including QTORIN

docetaxel, and its research-stage opportunities, including its expected therapeutic potential, and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to make regulatory submissions on anticipated timelines; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN docetaxel; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Vice President of Investor Relations and Corporate Affairs
Palvella Therapeutics
marcy.nanus@palvellatx.com